Skip to content

Clinical outcomes of artificial liver support treatments for critically ill patients with liver failure

Clinical outcomes of artificial liver support treatments for critically ill patients with liver failure

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
TCTR
Registry ID
TCTR20210924003
Enrollment
62
Registered
2021-09-24
Start date
2020-05-15
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver failure Acute liver failure Acute on chronic liver failure Hepatic encephalopathy Coagulopathy Hyperbilirubinemia Hyperammonia Uremia Liver failure Acute liver failure Acute on chronic liver failure Artificial liver support Extracorporeal liver support devices Plasma exchange Double plasma molecular adsorption system

Interventions

Liver failure cases that admitted to ICU during the study period of time and did not receive artificial liver support treatments.,Liver failure cases that admitted to ICU during the study period of ti
double plasma molecular adsorption system&#44
hemoperfusion&#44
Treatment,Treatment
Supportive medical treatment ,Artificial liver support

Sponsors

Faculty of Medicine, Siriraj Hospital, Mahidol University, Thailand
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Age > 18 years 2. Admitted to ICU 3. Diagnosed with liver failure as 3.1 Acute liver failure (ALF) as EASL 20171 and determined using King s College criteria or 3.2 Acute on chronic liver failure (ACLF) as APASL 20195 with MELD score at least 30 or AARC score higher or equal to 8

Exclusion criteria

Exclusion criteria: 1. Poor prognostic coexisting disease (e.g. advanced malignancy) 2. Uncontrolled bleeding or infections 3. Uncontrolled hemodynamics instability 4. HIV infection

Design outcomes

Primary

MeasureTime frame
28-day survival 28 days categorical data

Secondary

MeasureTime frame
90-day survival 90 days categorical data,Length of ICU stay until discharge from ICU continuous data,Bilirubin clearance rate until discharge from ICU or 7 days continuous data,Liver transplantation rate (in admission) until hospital discharge continuous data,Renal replacement therapy rate until discharge from ICU continuous data,Adverse events until discharge from ICU categorical data

Countries

Thailand

Contacts

Public ContactRanistha Ratanarat

Division of Critical Care, Department of Medicine Siriraj Hospital, Mahidol University

ranittha@hotmail.com0896685287

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Apr 4, 2026